Follow Us:
Metamizole

Novalgin

Metamizole

Metamizole (also known as dipyrone) is a non-opioid analgesic and antipyretic medicine used in some countries to manage moderate to severe pain and high fever when other treatments are unsuitable or ineffective. It works through mechanisms involving prostaglandin pathways and central pain-processing systems, although its exact mechanism is not fully understood. It is available in tablets, oral drops, and injectable formulations, depending on the country. Possible side effects include nausea, dizziness, and allergic reactions; a rare but serious risk is agranulocytosis, a potentially life-threatening reduction in white blood cells. Metamizole is restricted or not approved in some countries because of this risk, and patients should seek urgent medical attention for fever, sore throat, or mouth ulcers during treatment. It should be used only where approved and under appropriate medical supervision.

Dosage Form:
Dosage Strength:
CAS No.: 68-89-3
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Antipyretic Drugs
Class: Pyrazoline Derivatives

Uses of Metamizole

Metamizole was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Anti-inflammatory Activity: Selected derivatives have demonstrated potential to reduce inflammatory responses in experimental studies.
  • Analgesic Activity: Certain compounds have been investigated for their ability to reduce pain.
  • Antimicrobial Activity: Some derivatives have demonstrated antibacterial and antifungal properties in laboratory research.
  • Antioxidant Activity: Selected compounds have been studied for their potential to reduce oxidative stress.
  • Anticancer Research: Various pyrazoline derivatives are being investigated for their effects on cancer-cell growth and survival.
  • Anticonvulsant Research: Certain compounds have demonstrated potential anticonvulsant activity in experimental models.
  • Other Pharmacological Research: Additional studies have explored possible antidepressant and other biological activities.

Contraindication of Metamizole

Metamizole was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the active compound or its formulation ingredients.
  • Severe hepatic impairment where the compound is unsuitable.
  • Severe renal impairment where safe administration cannot be established.
  • Previous serious adverse reactions associated with the specific derivative.
  • Pregnancy or breastfeeding when established safety information indicates potential risks.
  • Specific blood disorders or other medical conditions that increase the risk of compound-related toxicity.

Precautions for Metamizole

Metamizole was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Allergic Reactions: Patients should be monitored for hypersensitivity reactions, including skin rashes, itching and swelling.
  • Liver Function: Caution may be necessary in patients with hepatic impairment, depending on the specific compound.
  • Kidney Function: Patients with renal impairment may require additional monitoring or dosage adjustments for certain derivatives.
  • Gastrointestinal Effects: Some pharmacologically active derivatives may cause nausea, abdominal discomfort or gastrointestinal irritation.
  • Blood Disorders: Potential effects on blood-cell production should be considered where supported by the compound's safety profile.
  • Pregnancy and Breastfeeding: Safety information may be limited, particularly for investigational derivatives. Medical advice is necessary before use.
  • Long-term Administration: Long-term safety should not be assumed from short-term laboratory or animal studies.

Drug Interactions for Metamizole

Potential drug interactions were historically documented when Metamizole was prescribed alongside certain medications. These included:

  • Anticoagulants: Additional monitoring may be necessary if a derivative affects bleeding risk or drug metabolism.
  • Antiplatelet Medicines: Concurrent administration may require caution where there is an increased risk of bleeding.
  • Other Anti-inflammatory Medicines: Combining compounds with similar pharmacological effects may increase adverse reactions.
  • Hepatotoxic Medicines: Concurrent use with medicines that can damage the liver may increase hepatic safety concerns.
  • Nephrotoxic Medicines: Combining certain derivatives with kidney-damaging medicines may increase renal risks.
  • Antibiotics and Antifungals: Metabolic interactions may occur depending on the enzymes involved in the metabolism of the individual compound.
  • Immunosuppressants: Additional monitoring may be necessary if the derivative affects immune function or drug metabolism.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Metamizole.

The Metamizole sodium is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Metamizole.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Metamizole, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Metamizole Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Metamizole

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Metamizole Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Metamizole, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Metamizole

The export of Metamizole from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Metamizole Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Metamizole specifications, certificates of analysis, and other supporting documents required for Metamizole export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Metamizole export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Metamizole regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Metamizole documentation, labelling, Metamizole manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Metamizole Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Metamizole, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.